Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype

被引:152
作者
Lowery, Maeve A. [1 ,2 ,3 ]
Jordan, Emmet J. [1 ]
Basturk, Olca [2 ,4 ]
Ptashkin, Ryan N. [4 ]
Zehir, Ahmet [4 ]
Berger, Michael F. [4 ,5 ]
Leach, Tanisha [2 ]
Herbst, Brian [2 ]
Askan, Gokce [2 ]
Maynard, Hannah [1 ]
Glassman, Danielle [1 ]
Covington, Christina [1 ]
Schultz, Nikolaus [5 ]
Abou-Alfa, Ghassan K. [1 ,3 ]
Harding, James J. [1 ,3 ]
Klimstra, David S. [4 ]
Hechtman, Jaclyn F. [5 ]
Hyman, David M. [1 ,3 ,5 ]
Allen, Peter J. [2 ,3 ]
Jarnagin, William R. [2 ,3 ]
Balachandran, Vinod P. [2 ,3 ]
Varghese, Anna M. [1 ,2 ,4 ]
Schattner, Mark A. [1 ,2 ]
Yu, Kenneth H. [1 ,2 ,4 ]
Saltz, Leonard B. [1 ,3 ]
Solit, David B. [1 ,3 ,5 ]
Iacobuzio-Donahue, Christine A. [2 ,4 ]
Leach, Steven D. [2 ,6 ]
O'Reilly, Eileen M. [1 ,2 ,3 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, David M Rubenstein Ctr Pancreat Canc Res, 1275 York Ave, New York, NY 10021 USA
[3] Weill Cornell Med Coll, Dept Med, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Ctr Mol Oncol, 1275 York Ave, New York, NY 10021 USA
[6] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA
关键词
CANCER; MUTATIONS;
D O I
10.1158/1078-0432.CCR-17-0899
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Molecular profiling in cancer has identified potential actionable drug targets that have prompted attempts to discover clinically validated biomarkers to guide therapeutic decision-making and enrollment to clinical trials. We evaluated whether comprehensive genetic analysis of patients with pancreatic adenocarcinoma is feasible within a clinically relevant timeframe and whether such analyses provide predictive and/or prognostic information along with identification of potential targets for therapy. Experimental Design: Archival or prospectively acquired FFPE samples and matched normal DNA from N = 336 patients with pancreatic cancer were analyzed using a hybridization capture-based, next-generation sequencing assay designed to perform targeted deep sequencing of all exons and selected introns of 410 key cancer-associated genes. Demographic and treatment data were prospectively collected with the goal of correlating treatment outcomes and drug response with molecular profiles. Results: The median time from protocol consent to reporting of the genomic results was 45 days with a median time from tissue delivery of 20 days. All genetic alterations identified were stratified based upon prior evidence that the mutation is a predictive biomarker of drug response using the MSKCC OncoKB classification. Three of 225 patients (1%) received a matched therapy based upon the sequencing results. Conclusions: The practical application of molecular results to guide individual patient treatment is currently limited in patients with pancreatic adenocarcinoma. Future prospective molecular profiling efforts should seek to incorporate routine germline genetic analysis and the identification of DNA profiles that predict for clinical benefit from agents that target DNA damage repair and or immunotherapy. (C) 2017 AACR.
引用
收藏
页码:6094 / 6100
页数:7
相关论文
共 19 条
[11]   Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials [J].
Le Tourneau, Christophe ;
Kamal, Maud ;
Tsimberidou, Apostolia-Maria ;
Bedard, Philippe ;
Pierron, Gaelle ;
Callens, Celine ;
Rouleau, Etienne ;
Vincent-Salomon, Anne ;
Servant, Nicolas ;
Alt, Marie ;
Rouzier, Roman ;
Paoletti, Xavier ;
Delattre, Olivier ;
Bieche, Ivan .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (04)
[12]   An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions [J].
Lowery, Maeve A. ;
Kelsen, David P. ;
Stadler, Zsofia K. ;
Yu, Kenneth H. ;
Janjigian, Yelena Y. ;
Ludwig, Emmy ;
D'Adamo, David R. ;
Salo-Mullen, Erin ;
Robson, Mark E. ;
Allen, Peter J. ;
Kurtz, Robert C. ;
O'Reilly, Eileen M. .
ONCOLOGIST, 2011, 16 (10) :1397-1402
[13]   Criteria for the use of omics-based predictors in clinical trials [J].
McShane, Lisa M. ;
Cavenagh, Margaret M. ;
Lively, Tracy G. ;
Eberhard, David A. ;
Bigbee, William L. ;
Williams, P. Mickey ;
Mesirov, Jill P. ;
Polley, Mei-Yin C. ;
Kim, Kelly Y. ;
Tricoli, James V. ;
Taylor, Jeremy M. G. ;
Shuman, Deborah J. ;
Simon, Richard M. ;
Doroshow, James H. ;
Conley, Barbara A. .
NATURE, 2013, 502 (7471) :317-320
[14]   Familial Pancreatic Adenocarcinoma [J].
Petersen, Gloria M. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (04) :641-+
[15]   Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States [J].
Rahib, Lola ;
Smith, Benjamin D. ;
Aizenberg, Rhonda ;
Rosenzweig, Allison B. ;
Fleshman, Julie M. ;
Matrisian, Lynn M. .
CANCER RESEARCH, 2014, 74 (11) :2913-2921
[16]   Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer [J].
Roberts, Nicholas J. ;
Norris, Alexis L. ;
Petersen, Gloria M. ;
Bondy, Melissa L. ;
Brand, Randall ;
Gallinger, Steven ;
Kurtz, Robert C. ;
Olson, Sara H. ;
Rustgi, Anil K. ;
Schwartz, Ann G. ;
Stoffel, Elena ;
Syngal, Sapna ;
Zogopoulos, George ;
Ali, Syed Z. ;
Axilbund, Jennifer ;
Chaffee, Kari G. ;
Chen, Yun-Ching ;
Cote, Michele L. ;
Childs, Erica J. ;
Douville, Christopher ;
Goes, Fernando S. ;
Herman, Joseph M. ;
Iacobuzio-Donahue, Christine ;
Kramer, Melissa ;
Makohon-Moore, Alvin ;
McCombie, Richard W. ;
McMahon, K. Wyatt ;
Niknafs, Noushin ;
Parla, Jennifer ;
Pirooznia, Mehdi ;
Potash, James B. ;
Rhim, Andrew D. ;
Smith, Alyssa L. ;
Wang, Yuxuan ;
Wolfgang, Christopher L. ;
Wood, Laura D. ;
Zandi, Peter P. ;
Goggins, Michael ;
Karchin, Rachel ;
Eshleman, James R. ;
Papadopoulos, Nickolas ;
Kinzler, Kenneth W. ;
Vogelstein, Bert ;
Hruban, Ralph H. ;
Klein, Alison P. .
CANCER DISCOVERY, 2016, 6 (02) :166-175
[17]   ATM Mutations in Patients with Hereditary Pancreatic Cancer [J].
Roberts, Nicholas J. ;
Jiao, Yuchen ;
Yu, Jun ;
Kopelovich, Levy ;
Petersen, Gloria M. ;
Bondy, Melissa L. ;
Gallinger, Steven ;
Schwartz, Ann G. ;
Syngal, Sapna ;
Cote, Michele L. ;
Axilbund, Jennifer ;
Schulick, Richard ;
Ali, Syed Z. ;
Eshleman, James R. ;
Velculescu, Victor E. ;
Goggins, Michael ;
Vogelstein, Bert ;
Papadopoulos, Nickolas ;
Hruban, Ralph H. ;
Kinzler, Kenneth W. ;
Klein, Alison P. .
CANCER DISCOVERY, 2012, 2 (01) :41-46
[18]   Whole genomes redefine the mutational landscape of pancreatic cancer [J].
Waddell, Nicola ;
Pajic, Marina ;
Patch, Ann-Marie ;
Chang, David K. ;
Kassahn, Karin S. ;
Bailey, Peter ;
Johns, Amber L. ;
Miller, David ;
Nones, Katia ;
Quek, Kelly ;
Quinn, Michael C. J. ;
Robertson, Alan J. ;
Fadlullah, Muhammad Z. H. ;
Bruxner, Tim J. C. ;
Christ, Angelika N. ;
Harliwong, Ivon ;
Idrisoglu, Senel ;
Manning, Suzanne ;
Nourse, Craig ;
Nourbakhsh, Ehsan ;
Wani, Shivangi ;
Wilson, Peter J. ;
Markham, Emma ;
Cloonan, Nicole ;
Anderson, Matthew J. ;
Fink, J. Lynn ;
Holmes, Oliver ;
Kazakoff, Stephen H. ;
Leonard, Conrad ;
Newell, Felicity ;
Poudel, Barsha ;
Song, Sarah ;
Taylor, Darrin ;
Waddell, Nick ;
Wood, Scott ;
Xu, Qinying ;
Wu, Jianmin ;
Pinese, Mark ;
Cowley, Mark J. ;
Lee, Hong C. ;
Jones, Marc D. ;
Nagrial, Adnan M. ;
Humphris, Jeremy ;
Chantrill, Lorraine A. ;
Chin, Venessa ;
Steinmann, Angela M. ;
Mawson, Amanda ;
Humphrey, Emily S. ;
Colvin, Emily K. ;
Chou, Angela .
NATURE, 2015, 518 (7540) :495-501
[19]   Distant metastasis occurs late during the genetic evolution of pancreatic cancer [J].
Yachida, Shinichi ;
Jones, Sian ;
Bozic, Ivana ;
Antal, Tibor ;
Leary, Rebecca ;
Fu, Baojin ;
Kamiyama, Mihoko ;
Hruban, Ralph H. ;
Eshleman, James R. ;
Nowak, Martin A. ;
Velculescu, Victor E. ;
Kinzler, Kenneth W. ;
Vogelstein, Bert ;
Iacobuzio-Donahue, Christine A. .
NATURE, 2010, 467 (7319) :1114-U126